ural huperzine A in studies.
Huperzine A has also been combined or hybridized with the prescripion drug tacrine (Cognex), an acetylcholinesterase inhibitor approved by the U.S. Food and Drug Administration (FDA) for treating Alzheimer's disease. The resulting huprine combination seems to be more effective at limiting acetylcholinesterase activity than either agent alone. Much more study needs to be done on the possible effects of huperzine A, huperzine B, huprine, and other chemicals derived fro